作者
Axel Nelson,Safa Alghaib,Karl Björkström,Karolin Isaksson,Ellen Krabbe,Sophie Orme,Måns Kadefors,Mikael Wallander,Sara Bjursten,Gustav Jörgen Ullenhag,Ana Carneiro,Hildur Helgadóttir,Lars Ny,Roger Olofsson Bagge
摘要
BACKGROUND: Circadian rhythms regulate immune cell trafficking and function, and emerging clinical data suggest that the timing of immune checkpoint inhibitor (ICI) administration may influence efficacy. In advanced disease, later-day administration has been associated with inferior outcomes. Whether this applies to neoadjuvant ICI in resectable stage III-IV melanoma is unknown. METHODS: This retrospective cohort study included patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI at four Swedish academic centers. Patients were categorized by timing of ICI across two infusions (morning, both <12:00; afternoon, both ≥12:00; mixed, one <12:00 and one ≥12:00). The primary endpoint was major pathological response. Secondary endpoints were event-free (EFS), distant metastasis-free (DMFS), melanoma-specific (MSS), and overall survival (OS). Associations were assessed using logistic regression and Cox models. RESULTS: A total of 265 patients were included (morning, n = 94; mixed, n = 96; afternoon, n = 75). Major pathological response rates were similar across groups (morning 47%, mixed 44%, afternoon 40%; p = 0.68). After a median follow-up of 17.4 months, morning administration was associated with a lower hazard of events across survival endpoints versus afternoon, including DMFS (HR 0.47, 95% CI 0.23-0.96), MSS (HR 0.18, 95% CI 0.04-0.71), and OS (HR 0.13, 95% CI 0.04-0.50) but not EFS (HR 0.58, 95% CI 0.31-1.08), compared with afternoon administration. Associations remained after adjustment for pathological response. CONCLUSIONS: Time of day of neoadjuvant ICI administration was not associated with pathological response. However, afternoon administration was associated with worse survival outcomes. These findings suggest treatment timing may influence long-term outcomes, although prospective validation is needed.